Quantum-Si Inc
quantum-si.comQuantum-Si Inc (NASDAQ: QSI) is a life sciences company focused on proteomics research that develops and sells next-generation protein sequencing instruments and consumables for laboratory researchers. Revenue comes from instrument sales and recurring consumable sales, with instruments priced at approximately $85,000 for the Platinum and approximately $120,000 for the Platinum Pro (as of the 10-K filed March 3, 2026). The company competes against mass spectrometry instrument makers and affinity-based proteomics tool providers, positioning its benchtop sequencers as lower-cost, single-molecule alternatives to mass spectrometry systems that can cost $1,000,000 or more. Founded in 2013 as Q-SI Operations Inc. and incorporated in Delaware in 2020, Quantum-Si completed a business combination in June 2021. The company moved to a full commercial launch of Platinum in Q2 2024 and began first shipments of Platinum Pro in March 2025. As of November 2024, the company employed 187 people before a restructuring that reduced headcount by approximately 23%. Jeffrey Hawkins serves as President and CEO.
Products & Services
Platinum benchtop next-generation protein sequencer (full commercial launch Q2 2024, priced ~$85,000); Platinum Pro benchtop sequencer (launched January 2025, first shipments March 2025, priced ~$120,000); Library Preparation Kits; Sequencing Kits; Platinum Analysis Software for automated data analysis and visualization. A future Proteus platform has been announced but not yet launched as of the filing date.
Revenue Model
Instrument sales (Platinum at ~$85,000, Platinum Pro at ~$120,000 per unit) combined with recurring consumable sales, specifically Library Preparation Kits and Sequencing Kits designed exclusively for use with Quantum-Si instruments. Consumables are proprietary to the platform, creating a captive recurring revenue stream tied to installed instrument base.
Customers & Markets
Life sciences researchers across academic, pharmaceutical, and clinical laboratory settings. End market is proteomics research, including protein isoform characterization, post-translational modification analysis, and broad proteome analysis. Customer funding is partially dependent on government and institutional research grants.
Financial Snapshot
Loading...
